Corporate Information – Page 32 – Alligator Bioscience

2019-07-31

Regulatory

Alligator Bioscience regains global rights from Janssen to CD40 agonistic antibody, ADC-1013 (JNJ-64457107)

Lund, Sweden, July 31, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that it has regained exclusive, worldwide righ ...

2019-06-18

Lund, Sweden, June 18, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutic ...

2019-06-18

Two Alligator projects presented at ASCO. "The American Society of Clinical Oncology (ASCO) is a professional organization for oncologis ...

2019-06-14

Two Alligator projects presented at ASCO. "The American Society of Clinical Oncology (ASCO) is a professional organization for oncologis ...

2019-05-16

Lund, Sweden, May 16, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that the outline of the ongoing Phase I study w ...

2019-05-15

Regulatory

Lund, Sweden, April 11, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that preclinical data on the CTLA-4 x OX40 bi ...